Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.

Biotechnology

Education

Escalier Biosciences

Escalier Biosciences' headquarters in Encinitas, CA, United States

Raju Mohan

Chris Krueger

John Nuss

James G. Krueger

Norman C. Selby

Emma Guttman-Yassky

Sander Van Deventer

Somu Subramaniam

Alexa B. Kimball

Edward Van Wezel

Willam Sandborn

The Advisory Board at Escalier Biosciences provides strategic guidance and expertise to support the development of innovative RORγt inverse agonists for psoriasis treatment. Composed of industry experts and thought leaders, the team offers insights on clinical trials, regulatory pathways, and market needs, ensuring that the company's therapies effectively address the needs of both mild-to-moderate and moderate-to-severe psoriasis patients.

Advisory Board

The Leadership Team at Escalier Biosciences is responsible for setting the overall strategic direction and vision of the company, guiding the development of innovative RORγt inverse agonists for psoriasis treatment. This team, composed of founding members and key executives, collaborates to align scientific research with business goals, ensuring effective resource allocation, regulatory compliance, and market entry strategies for both topical and oral therapeutic solutions.

Leadership Team

Escalier Biosciences

Org chart

Board & advisors

Teams

Advisory Board

Leadership Team

Offices

Escalier Biosciences

Org chart

Board & advisors

Teams

Advisory Board

Leadership Team

Offices

Related companies